Applying precision medicine
to find a better solution

Preserving future memories

Alzheon is a clinical-stage biopharmaceutical company with a Phase 3 program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders.

Explore the pipeline

Our science

Publications Peer-reviewed papers from our research programs and clinical trials.In the Media News coverage of Alzheon’s science and clinical progress.About Us Who we are, what we do and the mission guiding our work.

Our pipeline

Anti-aggregation Platform

Two clinical-stage oral programs and a small-molecule discovery library, united by one anti-aggregation mechanism and a decade of research into the biology of Alzheimer’s.

Lead program

Valiltramiprosate ALZ-801 · oral · twice-daily

MCI due to AD in APOE4/4 homozygotes
Anti-amyloid oligomer inhibitor

DiscoveryPhase 1Phase 2Phase 3

Phase 3 in Early AD completed

Clinical

ALZ-507 oral · once-daily

Alzheimer’s disease prevention
Next-generation anti-amyloid aggregation inhibitor & APOE4 corrector mechanism

DiscoveryPhase 1Phase 2Phase 3

First subject dosed in Phase 1

Discovery

Undisclosed small-molecule anti-aggregation library